Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
1(11%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_1
3
33%
Ph phase_2
6
67%

Phase Distribution

3

Early Stage

6

Mid Stage

0

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
3(33.3%)
Phase 2Efficacy & side effects
6(66.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

60.0%

3 of 5 finished

Non-Completion Rate

40.0%

2 ended early

Currently Active

1

trials recruiting

Total Trials

9

all time

Status Distribution
Active(2)
Completed(3)
Terminated(2)
Other(2)

Detailed Status

Completed3
Suspended2
Withdrawn2
Not yet recruiting1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
1
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 13 (33.3%)
Phase 26 (66.7%)

Trials by Status

not_yet_recruiting111%
recruiting111%
completed333%
suspended222%
withdrawn222%

Recent Activity

1 active trials
Showing 5 of 9
suspendedphase_2

Triage of Advanced Cervical Cancer Through Immunotherapy Induction (TRACTION)

NCT05475171
suspendedphase_2

Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial]

NCT07071961
recruitingphase_2

A Study of Lorigerlimab in Participants With Advanced Solid Tumors

NCT06730347
completedphase_2

A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer

NCT05848011
not_yet_recruitingphase_2

Lorigerlimab (MGD019) in Patients With Pancreatic Adenocarcinoma and Homologous Recombination Deficiency

NCT07565155
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT05475171Phase 2

Triage of Advanced Cervical Cancer Through Immunotherapy Induction (TRACTION)

Suspended
NCT07071961Phase 2

Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial]

Suspended
NCT06730347Phase 2

A Study of Lorigerlimab in Participants With Advanced Solid Tumors

Recruiting
NCT05848011Phase 2

A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer

Completed
NCT07565155Phase 2

Lorigerlimab (MGD019) in Patients With Pancreatic Adenocarcinoma and Homologous Recombination Deficiency

Not Yet Recruiting
NCT07137390Phase 1

A Trial of Regorafenib Plus Lorigerlimab as Neoadjuvant Therapy for Patients With pMMR/MSS, Resectable, Lung-limited Metastatic Colorectal Cancer

Withdrawn
NCT07223567Phase 2

A Trial of Regorafenib Plus Lorigerlimab in Patients With Locally Recurrent or Regrowing pMMR/MSS Localized Rectal Cancer

Withdrawn
NCT05293496Phase 1

A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors

Completed
NCT03761017Phase 1

MGD019 DART® Protein in Unresectable/Metastatic Cancer

Completed

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9